<DOC>
	<DOC>NCT02133612</DOC>
	<brief_summary>Esophageal cancer is a highly aggressive malignancy with a poor overall outcome. - Five year survival rate after radical esophagectomy is modest at about 40%.The patients with regional lymph node metastases have worse outcome than those without lymph node metastases. - No standard postoperative adjuvant chemotherapy has ever been established.</brief_summary>
	<brief_title>Adjuvant Chemotherapy With Paclitaxel and Cisplatin in Lymph Node-Positive Thoracic Esophageal Squamous Cell Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>ability to give informed consent histological proof of thoracic esophageal squamous cell carcinoma with negative proximal and distal margins nodepositive and pathologic stage M0 . Eastern Cooperative Oncology Group (ECOG) performance status 01 Patients were enrolled 4 to 10 weeks after surgery. Adequate organ function was required in 2 weeks of registration and was defined as: serum creatinine within normal institutional limit, and creatinine clearance (CrCl) ≥60ml/minute. Aspartate aminotransferase and bilirubin＜2 times of upper normal institutional limits. prior chemotherapy or concurrent radiation therapy before esophagectomy R1 or R2 resection clinically significant hearing loss or symptomatic peripheral neuropathy during initial examination</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>esophageal cancer</keyword>
	<keyword>adjuvant chemotherapy</keyword>
	<keyword>esophageal surgery</keyword>
	<keyword>paclitaxel</keyword>
	<keyword>cisplatin</keyword>
</DOC>